MARCKS and Miyoshi myopathy: Indeed, Muguruma and colleagues reported that selective targeting of PKC isoforms using enzastaurin (inhibits PKCβ) or Gö6976 (inhibits PKCα and β) proved insignificant in rescuing Jagged1-mediated phosphorylation of MARCKS and consequently the enhanced survival of bortezomib-resistant MM cells [18].